ABOD2011 in Patients With Advanced Solid Tumors Progressed After Standard Systemic Therapy

Phase 1 Recruiting 60 enrolled Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Non-randomizedParallel-groupOpen-labelTreatment

Summary

Based on the activation and regulation of immune system by cytokines, mRNA encoding cytokines has become one of the important directions of mRNA tumor drug development. This product (ABOD2011) is a new generation mRNA product for intratumoral injection. The primary objective of this study is to assess the safety and tolerability, of ABOD2011 in patients with advanced solid tumors that progressed after standard systemic therapy.

Timeline

Start: 2022-05-25
Primary completion: 2025-03
Completion: 2027-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	human single chain IL-12 mRNA	Messenger RNA (mRNA)	—	Intrathecal

Indications

No indication recorded.